Skip to main content
Fig. 5 | Journal of Ovarian Research

Fig. 5

From: Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells

Fig. 5

Signaling pathways involved in the treatment with ghrelin and cisplatin. A-B Western blotting analysis of the expression of p-ERK1/2 and p-p38 under treatment with ghrelin in time-dependent (10 nM) (A) and dose-dependent (B) manners for 20 min. C Western blotting analysis of the expression of p-ERK1/2 and p-p38 with the treatment of cisplatin for 12 h in dose-dependent manners. D Western blotting analysis of the expression of p-CDK1, cyclin B1, and p21 in HO-8910 PM treated with MAPK inhibitors (U0126 or SB202190, 5 μM, respectively), cisplatin and the combination of inhibitors with cisplatin for 12 h. Data are shown as the mean ± SD from three independent experiments. *p < 0.05

Back to article page